Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.
Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS. Koppelman B, et al. Among authors: almirez r. Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7. Pharmacology. 2008. PMID: 18176091
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. Medicherla S, et al. Among authors: almirez r. J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. doi: 10.1124/jpet.105.098020. Epub 2006 Apr 5. J Pharmacol Exp Ther. 2006. PMID: 16597712
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF. Medicherla S, et al. Among authors: almirez r. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. doi: 10.1124/jpet.105.097857. Epub 2006 Apr 7. J Pharmacol Exp Ther. 2006. PMID: 16603672
Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles.
Tan X, Tester RW, Luedtke GR, Chakravarty S, Mavunkel BJ, Perumattam JJ, Lu Q, Nashashibi I, Jung J, Hu J, Liclican A, Almirez R, Tabora J, Tran V, Laney M, Levy DE, Dugar S. Tan X, et al. Among authors: almirez r. Bioorg Med Chem Lett. 2010 Feb 1;20(3):828-31. doi: 10.1016/j.bmcl.2009.12.091. Epub 2010 Jan 4. Bioorg Med Chem Lett. 2010. PMID: 20071169
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. Uhl M, et al. Among authors: almirez r. Cancer Res. 2004 Nov 1;64(21):7954-61. doi: 10.1158/0008-5472.CAN-04-1013. Cancer Res. 2004. PMID: 15520202
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies.
Alfaro J, Pérez de Arce F, Belmar S, Fuentealba G, Avila P, Ureta G, Flores C, Acuña C, Delgado L, Gaete D, Pujala B, Barde A, Nayak AK, Upendra TVR, Patel D, Chauhan S, Sharma VK, Kanno S, Almirez RG, Hung DT, Chakravarty S, Rai R, Bernales S, Quinn KP, Pham SM, McCullagh E. Alfaro J, et al. Among authors: almirez rg. J Pharmacol Exp Ther. 2017 May;361(2):312-321. doi: 10.1124/jpet.116.238022. Epub 2017 Mar 15. J Pharmacol Exp Ther. 2017. PMID: 28298527
24 results